NCT05048849 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study | Biotech Hunter

Enrollment

274

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

November 8, 2021

Study Completion Date

April 12, 2022

Conditions

Covid19 Vaccine

Interventions

BIOLOGICAL

MVC-COV1901(S protein with adjuvant)

Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Trial Locations (11)

Unknown

Changhua Christian Hospital, Changhua

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

China Medical University Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

Taipei Medical University Hospital, Taipei

Taipei Municipal Wan Fang Hospital, Taipei

Taipei Veteran General Hospital, Taipei

Tri-Service General Hospital, Taipei

Chang-Guang Memorial Hospital Lin-Kou, Taoyuan District

Tao-Yuan General Hospital, Taoyuan District